<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">This clinical trial was funded by 
 <funding-source id="gs1">JCR Pharmaceuticals</funding-source>. The funder participated in the design of the trial, the collection, analysis and interpretation of the data, and the writing of the report; it also dealt with all the regulatory requirements for carrying out the trial. The funder is also the sole intellectual property holder as well as the manufacturer of the test drug JR-141. All authors had full access to the data used in the study, and the corresponding author had final responsibility for the completion of the manuscript and the decision to submit it for publication. T.O. reports research grants from 
 <funding-source id="gs2">Sanofi</funding-source>, 
 <funding-source id="gs3">JCR Pharmaceuticals</funding-source>, 
 <funding-source id="gs4">GC Pharma</funding-source>, 
 <funding-source id="gs5">Dainippon Sumitomo Pharma</funding-source>, 
 <funding-source id="gs6">Actelion</funding-source>, 
 <funding-source id="gs7">Alexion</funding-source>, and 
 <funding-source id="gs8">Anges</funding-source>, along with honoraria from 
 <funding-source id="gs9">Sanofi</funding-source>, 
 <funding-source id="gs10">Dainippon Sumitomo Pharma</funding-source>, Actelion, and Anges. Y.E. has conducted consultancy for JCR Pharmaceuticals, and he has been awarded grants and research support from Actelion, 
 <funding-source id="gs11">BioMarin Pharmaceutical Inc.</funding-source>, and Sanofi; he has also received honoraria from Actelion, BioMarin Pharmaceutical Inc., Sanofi, 
 <funding-source id="gs12">Shire</funding-source>, and Dainippon Sumitomo Pharma. N.S. has conducted consultancy for JCR Pharmaceuticals, and he has been awarded grant/research support from Sanofi and Dainippon Sumitomo Pharma and honoraria from Actelion, BioMarin Pharmaceutical Inc., Sanofi, Shire, and Dainippon Sumitomo Pharma.
</p>
